title: Alzheimer's disease & metals: therapeutic opportunities.
abstract: Alzheimer's disease (AD) is the most common age related neurodegenerative disease. Currently, there are no disease modifying drugs, existing therapies only offer short-term symptomatic relief. Two of the pathognomonic indicators of AD are the presence of extracellular protein aggregates consisting primarily of the Aβ peptide and oxidative stress. Both of these phenomena can potentially be explained by the interactions of Aβ with metal ions. In addition, metal ions play a pivotal role in synaptic function and their homeostasis is tightly regulated. A breakdown in this metal homeostasis and the generation of toxic Aβ oligomers are likely to be responsible for the synaptic dysfunction associated with AD. Therefore, approaches that are designed to prevent Aβ metal interactions, inhibiting the formation of toxic Aβ species as well as restoring metal homeostasis may have potential as disease modifying strategies for treating AD. This review summarizes the physiological and pathological interactions that metal ions play in synaptic function with particular emphasis placed on interactions with Aβ. A variety of therapeutic strategies designed to address these pathological processes are also described. The most advanced of these strategies is the so-called 'metal protein attenuating compound' approach, with the lead molecule PBT2 having successfully completed early phase clinical trials. The success of these various strategies suggests that manipulating metal ion interactions offers multiple opportunities to develop disease modifying therapies for AD.
authors.affiliation: The Mental Health Research Institute, The University of Melbourne, Parkville, Vic., Australia.
authors.forename: Vijaya B
authors.initials: VB
authors.lastname: Kenche
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Barnham
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000502:physiology; D000818:Animals; D001665:Binding Sites; D002412:Cations; D002986:Clinical Trials as Topic; D007464:Clioquinol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D056831:Coordination Complexes / Q000494:pharmacology / Q000627:therapeutic use; D003300:Copper / Q000502:physiology*; D006801:Humans; D018384:Oxidative Stress; D011485:Protein Binding; D013569:Synapses / Q000187:drug effects / Q000502:physiology; D015032:Zinc / Q000502:physiology*
chemical_list: D016229:Amyloid beta-Peptides; D002412:Cations; D056831:Coordination Complexes; C531955:PBT2 compound; D003300:Copper; D007464:Clioquinol; D015032:Zinc